Global specialty pharma company, Theramex, and private pharma company, Endoceutics, have entered into a definitive agreement for the exclusive licensing of Intrarosa (Prasterone) in Europe, Australia, Russia and the Ukraine.
Partnership
Intrarosa is a non-oestrogen prescription therapy that has been approved for the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women experiencing moderate to severe symptoms.
Anish Mehta, chief executive officer at Theramex said: “Intrarosa is a novel medicine that offers an effective treatment for a very common condition in postmenopausal women. We are pleased to be able to continue the ground-breaking work of Dr Fernand Labrie, the founder and chief executive officer of Endoceutics. With our strong heritage and commitment to women’s health, we are looking forward to making Intrarosa available to women to better address this condition.”
“Intrarosa is an excellent addition to our portfolio of products that help women manage the symptoms of menopause. This deal is an example of our commitment to become the leading healthcare company dedicated to women’s health,” she added.
“As a non-oestrogen treatment, Intrarosa is a novel vaginal prescription therapy that locally replaces inside the cells what is missing for patients with vulvovaginal atrophy. Intrarosa improves the body's natural ability to produce hormones locally and intracellularly, thus correcting the symptoms, such as pain during sexual activity, without influencing other tissues,” comented Labrie, founder and chief executive officer of Endoceutics. “Since Intrarosa is not an oestrogen-based product, patients should feel more comfortable seeking a treatment in line with physiology and all circulating steroids remaining within normal values.
“I’m pleased to be working closely with Theramex, a company that shares our vision of helping women live better, symptom-free lives. I believe their expertise and knowledge of the women’s health community will make Intrarosa accessible to women across countries including those in Europe, Russia and Australia who presently struggle to find effective solutions for these very intimate, and yet very common, symptoms of menopause.”
While the deal terms have not been disclosed, countries within the license agreement are: Australia, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Poland, Romania, Serbia, Slovakia, Slovenia, UK, the Russian Federation, Kazakhstan, and the Ukraine.
The therapy received FDA approval for the treatment of moderate to severe dyspareunia (a symptom of VVA) in November 2016 and by the EMA for the treatment of VVA in January 2018.